EMA Application withdrawn: Blectifor (Caffeine citrate) — Viridian Pharma Ltd

View source ↗

Summary

The EMA withdrew the application for Blectifor (caffeine citrate) by Viridian Pharma in relation to bronchopulmonary dysplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• Blectifor (caffeine citrate)

Snippet

Status: Application withdrawn. Therapeutic area: Bronchopulmonary Dysplasia. MAH: Viridian Pharma Ltd. Decision date: 24/03/2017. Orphan medicine